Trial characteristics, methods and reported challenges of decentralised clinical trials: a scoping review

分散式临床试验的试验特征、方法及已报告的挑战:范围界定综述

阅读:2

Abstract

OBJECTIVES: To map the landscape of decentralised clinical trials (DCTs) by summarising characteristics, methods and reported challenges of published DCTs. DESIGN: Scoping review, reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR) checklist. DATA SOURCES: Ovid MEDLINE and PubMed were searched through to 21 August 2024. ELIGIBILITY CRITERIA: We included reports of completed DCTs (defined as a trial of an intervention, with a comparison arm, in which some or all trial activities occurred away from the trial centre). All intervention types were included. DATA EXTRACTION AND SYNTHESIS: A single reviewer extracted data to a structured extraction sheet. Descriptive statistics (frequencies) are reported for study characteristics and the terminology used to describe trial methods. Decentralised methods used were coded separately for each trial stage. RESULTS: 53 papers met inclusion criteria. Most studies (34/53) were conducted in the USA. Mental health (18 studies) and COVID-19 (11 studies) were the predominant research areas. 24 (of 53) studies investigated pharmaceutical interventions, while others examined nutritional interventions, medical devices and behavioural interventions. Recruitment, screening and consent were commonly conducted remotely. A range of methods, including online, in-person and telemedicine, was used to collect outcome measures. Several studies experienced challenges related to participant retention and biased recruitment. Terminology regarding decentralisation was inconsistent across studies. CONCLUSIONS: DCTs are rapidly increasing in use, and commonly cited advantages include reduced costs and reduced participant burden. This review identifies key research areas using DCTs and highlights a need for standardised terminology, comprehensive reporting of methods and limitations, and robust regulatory frameworks. Development of formal ethical and reporting standards is essential to ensure effective and responsible implementation of DCTs in clinical research.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。